CytoSorb® Registered and Commercially Available in Singapore
CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical
News provided by
Share this article
MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in the intensive care unit (ICU) and cardiac surgery, announces that the Singapore Health Sciences Authority (HSA) has now approved registration of CytoSorb® for all equivalent European Union (E.U.) approved indications, including the reduction of cytokine storm, the reduction of bilirubin in liver disease, the reduction of myoglobin in trauma, and the removal of ticagrelor and rivaroxaban during urgent or emergent cardiothoracic surgery.